Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted. The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of card
Biotechnologies, Pharmaceutique, Santé
2026-07-28 12:14 PM EDT | Hemostemix Inc.
AAMI Surveys Cardiac Health Professionals on Battery Longevity Management of Pacemakers
Arlington, Virginia--(Newsfile Corp. - July 28, 2026) - The Association for the Advancement of Medical Instrumentation (AAMI) officially announces the publication of a new guidance document on battery longevity management for implantable cardiac pacemakers and related devices. Given the limits of existing industry standards for cardiovascular implantable electronic device safety, there is significant variation among devices
2026-07-28 8:50 AM EDT | Association for the Advancement of Medical Instrumentation
George E. Norcross III to Donate $100 Million to Cooper University Health Care/MD Anderson Cancer Center at Cooper in Honor of His Parents, George E. Norcross Jr. and Anne Carol Conner Norcross
Camden, New Jersey--(Newsfile Corp. - July 28, 2026) - Cooper University Health Care Board of Trustees Executive Chairman, Co-President and Co-Chief Executive Officer Anthony J. Mazzarelli, MD, and the Board of Trustees today announced a transformational $100 million
2026-07-28 8:00 AM EDT | Cooper University Health Care
Apptly's UberDoc Partners with Bryleos, Bringing Woman-Owned Cellular-Health Innovator onto the Marketplace
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "the Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced a strategic partnership with Bryleos (BioNADrx Holdings, Inc.), a woman-owned life sciences company focused on NAD+ science and oral cellular-health formulations. Highlights: Marketplace Onboarding: Bryleos joins the
2026-07-28 8:00 AM EDT | Apptly Health Technologies Corp.
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the r
Biotechnologies, Pharmaceutique, Santé
2026-07-28 8:00 AM EDT | BioHarvest Sciences Inc.
NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free drug delivery, today announced the filing of two additional patent applications supporting its current patent portfolio. The new applications focus on high-efficiency spring charging technology and automatic dose-establishment technology. Together with previously announced patent applications relating to the Company's dual-spring
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-27 5:15 PM EDT | NuGen Medical Devices Inc.
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated June 12, 2026, May 12, 2026 and April 22, 2026, it has closed a third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Offering"), which Third Tranche consisted of the issuance of 8,0
Biotechnologies, Pharmaceutique, Santé
2026-07-27 5:12 PM EDT | PreveCeutical Medical Inc.
MNDR and Jospong Form Exclusive Joint Venture to Launch AI-Powered Digital Healthcare Ecosystem in Ghana
Singapore and Accra, Ghana--(Newsfile Corp. - July 27, 2026) - Mobile-health Network Solutions Inc. (NASDAQ: MNDR) ("MNDR" or the "Company"), an AI-powered digital healthcare platform company, and Jospong Group of Companies Limited ("Jospong"), a diversified Ghanaian conglomerate, today announced the signing of a definitive Joint Venture (JV). Agreement to establish MHNS Ghana Limited, a JV with exclusive rights to deploy and operate MNDR's digital healthcare ecosystem in Ghana
2026-07-27 9:25 AM EDT | Mobile-health Network Solutions
Optimind Pharma Announces Adoption of Semi-Annual Reporting
Toronto, Ontario--(Newsfile Corp. - July 24, 2026) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntari
Biotechnologies, Cannabis, Santé, Psychédéliques
2026-07-24 9:04 AM EDT | Optimind Pharma Corp.
TelyRx to Host Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - July 24, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended
Soins de santé et hôpitaux, Santé
2026-07-24 7:35 AM EDT | TelyRx
One Hemp Welcomes Bipartisan Push for Common-Sense Hemp Regulation
Washington, D.C.--(Newsfile Corp. - July 23, 2026) - ONE HEMP, a national coalition representing responsible hemp businesses and advocates, today welcomed the introduction of the bipartisan Lawful Hemp Protection Act, introduced by Reps. Andy Barr (R-KY) and Angie Craig (D-MN), calling it a significant step toward a responsible, federally regulated hemp marketplace that protects consumers without dismantling a vital American industry. The bill would establish federal standards for hemp
2026-07-23 8:08 AM EDT | OneHemp
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments
Soins de santé et hôpitaux, Santé
2026-07-23 1:01 AM EDT | Cosmo Pharmaceuticals N.V.
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants. Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant,
Biotechnologies, Pharmaceutique, Santé
2026-07-22 4:50 PM EDT | Hemostemix Inc.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.
MNDR Wins 2026 Technology for Good Award, Featuring Aiko in Its AI Intelligent Healthcare Ecosystem
Singapore, Singapore--(Newsfile Corp. - July 22, 2026) - Mobile-health Network Solutions Inc. (NASDAQ: MNDR) ("MNDR"), an AI-powered intelligent healthcare ecosystem, today announced it has been awarded the 2026 Technology for Good Distinction Award, following its recognition in 2025. This year's award highlights MNDR's AI Intelligent Healthcare Ecosystem, anchored by Aiko — the Agentic Patient Companion. Powered by MNDR's proprietary PhiGPT clinical
2026-07-22 8:38 AM EDT | Mobile-health Network Solutions
Altrova Health Provides Corporate Update: New OTCQB Symbol, O-Spray Commercial Progress, Additional NIRLAB Device Sale, and Rapid Detection Strip Expansion
Toronto, Ontario--(Newsfile Corp. - July 22, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to provide shareholders with an update across several areas of its business. New OTCQB Trading Symbol The Company's common shares commenced trading on the OTCQB under the new ticker symbol "ATVHF," effective as of market open on July 17, 2026, replacing the Company's prior symbol "SSPLF." The change does
2026-07-22 7:08 AM EDT | Altrova Health Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Binding Letter of Intent to Acquire Evergreen Pharmacy; Expected to Add Over US$78 Million in Annual Revenue
Custom Health has entered into a binding letter of intent (the "LOI") to acquire Evergreen Pharmacy LLC ("Evergreen"), a Wisconsin-based specialty pharmacy specializing in the management of complex therapies for chronic disease states. Evergreen generated Revenue of approximately US$78.8 million with Normalized EBITDA (1) of US$0.60 million, for the twelve-month period ended December 31, 2025. Evergreen is a profitable company on both EBITDA an
Technologies, Pharmaceutique, Santé
2026-07-22 6:30 AM EDT | Custom Health Holdings Inc.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.